Ureter Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy and radiation therapy.
The ureter cancer pipeline drugs market research report provides an analysis of the ureter cancer drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases covering the product development milestones. Additionally, the report provides an overview of key players involved in therapeutic development for ureter cancer and features dormant and discontinued projects.
Ureter Cancer Pipeline Drugs Market Segmentation by Targets
Some of the targets of the ureter cancer pipeline drugs market are Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit and Programmed Cell Death 1 Ligand 1 among others.
Ureter Cancer Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Ureter Cancer Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action of the ureter cancer pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor and Programmed Cell Death Protein 1 Antagonist among others.
Ureter Cancer Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Ureter Cancer Pipeline Drugs Market Segmentation by Routes of Administration
The routes of administration in the ureter cancer pipeline drugs market are intravenous, oral, intravenous drip, subcutaneous, intravesical, parenteral and intratumor.
Ureter Cancer Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Ureter Cancer Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the ureter cancer pipeline drugs market are monoclonal antibody, small molecule, monoclonal antibody conjugated, gene-modified cell therapy, subunit vaccine, fusion protein, and mRNA vaccine.
Ureter Cancer Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Competitive Landscape
Some of the leading companies in the ureter cancer pipeline drugs market are Exelixis Inc, Astellas Pharma Inc, AstraZeneca Plc, BeiGene Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, Merck KGaA, and Pfizer Inc among others.
Ureter Cancer Pipeline Drugs Market, by Leading Companies
For more insights on leading companies, download a free report sample
Ureter Cancer Pipeline Drugs Market Report Overview
Key Targets | Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit and Programmed Cell Death 1 Ligand 1 |
Key Mechanisms of Action | Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor and Programmed Cell Death Protein 1 Antagonist |
Key Routes of Administration | Intravenous, Oral, Intravenous Drip, Subcutaneous, Intravesical, Parenteral and Intratumor |
Key Molecule Types | Monoclonal Antibody, Small Molecule, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Subunit Vaccine, Fusion Protein, and mRNA vaccine |
Key Companies | Exelixis Inc, Astellas Pharma Inc, AstraZeneca Plc, BeiGene Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, Merck KGaA, and Pfizer Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape Ureter Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ureter (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aravive Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Dragonfly Therapeutics Inc
Exelixis Inc
Genentech USA Inc
Gilead Sciences Inc
GlyTherix Ltd
Hangzhou DAC Biotech Co Ltd
IO Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Kyowa Kirin Co Ltd
MacroGenics Inc
MedPacto Inc
Merck & Co Inc
Merck KGaA
Pfizer Inc
PsiOxus Therapeutics Ltd
RemeGen Co Ltd
Shandong New Time Pharmaceutical Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shionogi & Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the ureter cancer pipeline drugs market?
Some of the targets of the ureter cancer pipeline drugs market are Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit and Programmed Cell Death 1 Ligand 1 among others.
-
What are the mechanisms of action of the ureter cancer pipeline drugs market?
The key mechanism of action of the ureter cancer pipeline drugs market are Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor and Programmed Cell Death Protein 1 Antagonist among others.
-
What are the routes of administration in the ureter cancer pipeline drugs market?
The routes of administration in the ureter cancer pipeline drugs market are intravenous, oral, intravenous drip, subcutaneous, intravesical, parenteral and intratumor.
-
What are the molecule types in the ureter cancer pipeline drugs market?
The molecule types in the ureter cancer pipeline drugs market are monoclonal antibody, small molecule, monoclonal antibody conjugated, gene-modified cell therapy, subunit vaccine, fusion protein, and mRNA vaccine.
-
Which are the leading companies in the ureter cancer pipeline drugs market?
Some of the leading companies in the ureter cancer pipeline drugs market are Exelixis Inc, Astellas Pharma Inc, AstraZeneca Plc, BeiGene Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, Merck KGaA, and Pfizer Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.